Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands

Eline Boon, Wim van Boxtel, Jan Buter, Robert J. Baatenburg de Jong, Robert J.J. van Es, Miranda Bel, Edward Fiets, Sjoukje F. Oosting, Marije Slingerland, Ann Hoeben, Margot E.T. Tesselaar, Marianne A. Jonker, Uta E. Flucke, Winette T.A. van der Graaf, Carla M.L. van Herpen

Research output: Contribution to journalArticleAcademicpeer-review

88 Citations (Scopus)


Background: Salivary duct carcinoma, an aggressive subtype of salivary gland cancer, is mostly androgen receptor-positive. Only limited data are available on androgen deprivation therapy (ADT). Methods: Patients with advanced androgen receptor-positive salivary duct carcinoma treated with first-line ADT were retrospectively evaluated for clinical benefit (ie, partial response [PR] and stable disease, progression-free survival [PFS] and overall survival [OS]). The OS was compared with patients with advanced salivary duct carcinoma who received best supportive care. Results: Thirty-four of 35 patients who were ADT-treated were evaluable: 6 patients had a PR (18%) and 11 had stable disease (32%) leading to a clinical benefit ratio of 50%. The median PFS for the ADT-treated patients was 4 months and the median duration of clinical benefit was 11 months. The median OS was 17 months versus 5 months in 43 patients receiving best supportive care (P=.02). Conclusion: We recommend ADT in advanced androgen receptor-positive salivary duct carcinoma given its response and clinical benefit.

Original languageEnglish
Pages (from-to)605-613
Number of pages9
JournalHead and Neck
Issue number3
Publication statusPublished - 1 Mar 2018


  • Androgen deprivation therapy
  • Androgen receptors
  • Antineoplastic agents
  • Hormonal
  • Salivary duct carcinoma
  • Salivary gland neoplasms

Cite this